SV Life Sciences was started in London as Schroder Ventures Life Sciences in 1993 as part of the Schroder Ventures Group. The company's first fund closed in 1994 raising $100m. SV Life Sciences now has five funds with current committed capital of approximately $1.5 billion. Its team of 32 professionals are located in offices in Boston, London and San Francisco. SV Life Sciences became independent of the Schroder Ventures Group in 2001, and in January 2005 changed its name to SV Life Sciences to reflect independent ownership.
SV Life Sciences is a venture capital adviser and manager that makes selected investments in entrepreneurs and management teams.
SV Life Sciences provides finance to businesses at all stages of development and across the human life sciences sector. These sectors range from biotechnology & pharmaceuticals to medical devices & instruments, to healthcare information technology and services.
SV Life Sciences currently advises or manages five funds with capital commitments of approximately $1.5 billion which primarily invest amounts of between $1m and $40m in North America and Europe, but will consider innovative investments in other regions.
Our team of 32 professionals has a diverse, complimentary set of skills and experience that allow us to tailor a team to work with almost any life sciences business.
Tuna fishing season in the Pacific Ocean began Mexico
The National Aquaculture and Fisheries Commission (CONAPESCA) announced that on Monday, January 20, the tuna fishing season began with purse-seine vessels in the Pacific Ocean.